# Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma

> **NCT03505944** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Nordic Lymphoma Group** · enrollment: 59 (actual)

## Conditions studied

- Relapsed Non Hodgkin Lymphoma

## Interventions

- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03505944
- **Lead sponsor:** Nordic Lymphoma Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2021-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03505944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03505944, "Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03505944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*